These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34099386)

  • 1. Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study.
    Haber Z; Lee EW; Price M; Wainberg Z; Hecht JR; Sayre J; Padia SA
    Acad Radiol; 2021 Nov; 28 Suppl 1():S210-S217. PubMed ID: 34099386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 3. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
    Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
    Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
    Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
    Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
    Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
    J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
    Maleux G; Deroose C; Laenen A; Verslype C; Heye S; Haustermans K; De Hertogh G; Sagaert X; Topal B; Aerts R; Prenen H; Vanbeckevoort D; Vandecaveye V; Van Cutsem E
    Acta Oncol; 2016; 55(4):486-95. PubMed ID: 26625262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization.
    Schonewolf CA; Patel B; Gensure RH; Narra V; Haffty BG; Nosher JL; Jabbour SK
    Am J Clin Oncol; 2014 Jun; 37(3):234-40. PubMed ID: 23275270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-Based Integration of Yttrium-90 Radioembolization in the Contemporary Management of Hepatic Metastases from Colorectal Cancer.
    Wang DS; Louie JD; Sze DY
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):74-80. PubMed ID: 31079714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.
    Saxena A; Bester L; Shan L; Perera M; Gibbs P; Meteling B; Morris DL
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):537-47. PubMed ID: 24318568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
    Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
    Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?
    Sangha BS; Nimeiri H; Hickey R; Salem R; Lewandowski RJ
    Curr Treat Options Oncol; 2016 Jun; 17(6):26. PubMed ID: 27098532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.
    Damm R; Seidensticker R; Ulrich G; Breier L; Steffen IG; Seidensticker M; Garlipp B; Mohnike K; Pech M; Amthauer H; Ricke J
    BMC Cancer; 2016 Jul; 16():509. PubMed ID: 27439702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
    Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
    Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases.
    Seidensticker R; Denecke T; Kraus P; Seidensticker M; Mohnike K; Fahlke J; Kettner E; Hildebrandt B; Dudeck O; Pech M; Amthauer H; Ricke J
    Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1066-73. PubMed ID: 21800231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of 90Y-Radioembolization in Metastatic Colorectal Cancer Depending on the Primary Tumor Side.
    Schindler P; Masthoff M; Harders F; Schmidt HH; Stegger L; Pascher A; Rahbar K; Wildgruber M; Köhler M
    Dig Dis; 2021; 39(4):351-357. PubMed ID: 33142291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
    Mulcahy MF; Mahvash A; Pracht M; Montazeri AH; Bandula S; Martin RCG; Herrmann K; Brown E; Zuckerman D; Wilson G; Kim TY; Weaver A; Ross P; Harris WP; Graham J; Mills J; Yubero Esteban A; Johnson MS; Sofocleous CT; Padia SA; Lewandowski RJ; Garin E; Sinclair P; Salem R;
    J Clin Oncol; 2021 Dec; 39(35):3897-3907. PubMed ID: 34541864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.